Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 6/20 | 0.47 |
| ▸ | CNR2 | P34972 | 6/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.41 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.41 |
| ▸ | TLR4 | O00206 | 4/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17208465 | 0.86 | MAPK1 (0.45) | MAPK1CNR1CNR2TRPV1 | |
| SCHEMBL16694432 | 0.81 | MAPK1 (0.87) | MAPK1LGALS8LGALS3LGALS4TLR4 | |
| SCHEMBL17208459 | 0.81 | MAPK1 (0.87) | MAPK1LGALS8LGALS3LGALS4TLR4 | |
| SCHEMBL17091443 | 0.81 | MAPK1 (0.87) | MAPK1LGALS8LGALS3LGALS4TLR4 | |
| SCHEMBL17091444 | 0.81 | MAPK1 (0.87) | MAPK1LGALS8LGALS3LGALS4TLR4 | |
| SCHEMBL24916781 | 0.78 | MAPK1 (0.45) | MAPK1LGALS8LGALS3LGALS4 | |
| Methacrylic Acid SCHEMBL21879320 | 0.76 | MAPK1 (0.77) | MAPK1LGALS8LGALS3LGALS4TLR4 | |
| SCHEMBL4320956 | 0.75 | MAPK1 (0.52) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL25625445 | 0.75 | MAPK1 (0.52) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL7893025 | 0.75 | MAPK1 (0.38) | MAPK1LGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150307539-A1 | USE OF SULPHATED GLYCOLIPIDS AS PROMOTERS OF NEURITIC GROWTH, MYELINATION AND INHIBITING THE PROLIFERATION OF ASTROGLIA AND MICROGLIA | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307539-A1 | USE OF SULPHATED GLYCOLIPIDS AS PROMOTERS OF NEURITIC GROWTH, MYELINATION AND INHIBITING THE PROLIFERATION OF ASTROGLIA AND MICROGLIA | BDNF, MAG, NTRK2 | MAPK1 91/4885CNR1 645/4885CNR2 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.